Brief: Acurx Presents Positive Ibezapolstat Microbiome Data From Its Phase 2A Trial At IDWeek
04/10/2021 14:05
Oct 4 (Reuters) - Acurx Pharmaceuticals Inc ACXP.O :
* ACURX PRESENTS POSITIVE IBEZAPOLSTAT MICROBIOME DATA FROM
ITS
PHASE 2A TRIAL AT IDWEEK
* ACURX PHARMACEUTICALS INC - PH2A TRIAL DEMONSTRATED 100%
CLINICAL CURE AND SUSTAINED CLINICAL CURE
Source text for Eikon: ID:nPnbDQQ22a
Further company coverage: ACXP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acurx Pharmaceuticals
See all newsAcurx Pharmaceuticals Q1 net loss narrows as expenses fall
Brief: Acurx Pharmaceuticals To Discuss First Quarter 2026 Financial Results On May 12, 2026 Conference Call And Provide Business Update
Brief: Acurx Pharmaceuticals, Inc. Announces Closing Of Up To $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Acurx Pharmaceuticals Q4 net loss narrows on lower R&D spend
Acurx Pharma Q3 net loss narrows to $2 mln